Researchers sought to determine whether combining enasidenib with venetoclax would be effective in patients with IDH2-mutated ...

A breast cancer drug paired with venetoclax significantly enhanced leukemia cell killing and durability in preclinical tests.

OHSU researchers found that combining venetoclax with breast cancer drug palbociclib strongly improves AML treatment by ...

Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...

A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...

Tatiana Schlossberg, President John F. Kennedy's granddaughter, has died. Here's what to know about acute myeloid leukemia ...

Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...

First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...